ACIU AC Immune SA

12.71
-0.01  -0.08%
Previous Close 12.72
Open 12.48
Price To book 4.34
Market Cap 629.69M
Shares 49,543,000
Volume 20,268
Short Ratio 21.75
Av. Daily Volume 91,668

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence 2017. IPO September 23, 2016.
ACI-35 (anti-tau vaccine)
Alzheimer’s disease
Phase 1/2 ongoing. IPO September 23, 2016.
ACI-24 (anti-Abeta vaccine )
Alzheimer’s disease
Phase 3 trial commenced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016.
Crenezumab
Alzheimer’s disease

Latest News

  1. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 16, 2017
  2. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 5, 2017
  3. AC Immune SA – Value Analysis (NASDAQ:ACIU) : December 23, 2016
  4. AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : December 22, 2016
  5. Here is What Hedge Funds Think About AC Immune Ltd (ACIU)
  6. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : December 12, 2016
  7. AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB
  8. Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’
  9. Astra, Lilly stick with Alzheimer's approach despite setback
  10. Astra, Lilly stick with Alzheimer's approach despite setback
  11. AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER
  12. AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER
  13. AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
  14. Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know
  15. AC Immune SA announces results of annual general meeting
  16. AC Immune SA Reports Third Quarter 2016 Results
  17. Apptio and AC Immune Get Mixed Post-IPO Analyst Coverage at End of Quiet Period
  18. Alzheimer's Remains a Top Priority for Big Pharma
  19. AC Immune SA: Price momentum supported by strong fundamentals
  20. AC Immune SA Announces Pricing of Upsized Initial Public Offering